University of Sussex
Browse

File(s) under permanent embargo

Elacytarabine in relapsed/refractory acute myeloid leukaemia: an evaluation of clinical efficacy, pharmacokinetics, cardiac safety and effects on lipid profile

journal contribution
posted on 2023-06-08, 17:16 authored by Steven Knapper, Timothy ChevassutTimothy Chevassut, Rafael Duarte, Juan Miguel Bergua, Olga Salamero, Malin Johansen, Tove Flem Jacobsen, Petter-Arnt Hals, Wenche Rasch, Athos Gianella-Borradorif, Matthew Smith
Elacytarabine is the elaidic acid ester derivative of cytarabine, designed to enter cells independently of nucleoside transporters. Effects of elacytarabine on QT interval, serum lipid profile and clinical activity were investigated in 43 relapsed/refractory AML patients. Mean maximum increase in corrected QT interval of 24( ± 29)ms occurred 48 h after elacytarabine infusion without associated arrhythmias or clinical symptoms. A non-clinically significant, elacytarabine exposure-dependent increase in cholesterol was caused by a cholesterol rich lipoprotein depleted of apolipoprotein B formed by infused phospholipids complexing cholesterol. Elacytarabine is clinically active in relapsed/refractory AML: overall response rate (CR + CRi) was 44% (16/36 with 7 non-evaluable patients) and adverse events were manageable.

History

Publication status

  • Published

File Version

  • Published version

Journal

Leukemia Research

ISSN

0145-2126

Publisher

Elsevier

Issue

3

Volume

38

Page range

346-351

Department affiliated with

  • Clinical and Experimental Medicine Publications

Research groups affiliated with

  • Haematology Research Group Publications

Full text available

  • No

Peer reviewed?

  • Yes

Legacy Posted Date

2014-05-14

First Compliant Deposit (FCD) Date

2014-05-13

Usage metrics

    University of Sussex (Publications)

    Categories

    No categories selected

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC